Product Information

RESTASIS 0.05% EYE EMULSION is a brand product labeled by Allergan, Inc., priced at $10.3166 per EA under NDC 00023916360. Its NADAC has been published 665 times since Nov 28, 2013.

FDA first approved this application on Dec 23, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the cyclosporine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

RESTASIS 0.05% EYE EMULSION

cyclosporine
$10.3166per EA
High Outlier

Strength

.5 mg/mL

Manufacturer

Allergan, Inc.

NDC

00023916360

Classification

Brand

Dosage Form

EMULSION

Route

OPHTHALMIC

Effective Date

8/19/2026

Active Ingredients

CYCLOSPORINE

Approval Type

New Drug (NDA)

FDA Application

NDA050790

FDA Approved

12/23/2002

TE Code

AB

On Market Since

4/1/2003

Pharmacological Classes

Calcineurin Inhibitor Immunosuppressant
Calcineurin Inhibitors
Cytochrome P450 3A4 Inhibitors
P-Glycoprotein Inhibitors

Price Statistics

The NADAC for RESTASIS 0.05% EYE EMULSION has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 115.1%. The table below summarizes its recorded NADAC range and movement.

Current price$10.3166 per EA
All-time high$10.3396 (Mar 15, 2023)
All-time low$4.7953 (Nov 28, 2013)
52-week high$10.3248
52-week low$10.3166
Median price$9.3687
Average price$8.6421
Largest weekly change+9.9% (Jan 13, 2016)
Weeks tracked665
Tracking sinceNov 28, 2013

Price History

1W

-0.0%

1M

-0.0%

3M

-0.0%

6M

-0.0%

1Y

-0.1%

3Y

+0.0%

5Y

+4.9%

All

+115.1%

Generic Alternatives

The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 91% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of RESTASIS 0.05% EYE EMULSION?

The current National Average Drug Acquisition Cost (NADAC) for RESTASIS 0.05% EYE EMULSION, manufactured by Allergan, Inc., is $10.3166 per EA (NDC 00023916360), effective Aug 19, 2026.

How has the price of RESTASIS 0.05% EYE EMULSION changed over time?

Over the history we have for it, the NADAC for RESTASIS 0.05% EYE EMULSION has risen 115.1%. It has been tracked across 665 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for RESTASIS 0.05% EYE EMULSION?

Since Nov 28, 2013, the NADAC for RESTASIS 0.05% EYE EMULSION has ranged from a low of $4.7953 (Nov 28, 2013) to a high of $10.3396 (Mar 15, 2023), with a median of $9.3687 per EA.

Are there cheaper alternatives to RESTASIS 0.05% EYE EMULSION?

Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CYCLOSPORINE 0.05% EYE EMULSION, is $0.9240 per EA — about 91% below RESTASIS 0.05% EYE EMULSION.

Who manufactures RESTASIS 0.05% EYE EMULSION?

RESTASIS 0.05% EYE EMULSION (NDC 00023916360) is labeled by Allergan, Inc., and CMS classifies it as a brand product.